Highlight Pharmaceutical's Jinnoxitinib (TLL-018) Receives Breakthrough Therapy Designation from CDE for Rheumatoid Arthritis

For rheumatoid arthritis patients who've exhausted treatment options, hope may be on the way.

Hangzhou Highlight Pharmaceutical Co., Ltd. announced Tuesday that its oral drug candidate TLL-018 has received Breakthrough Therapy Designation from China's Center for Drug Evaluation. The designation covers treatment of rheumatoid arthritis, a chronic autoimmune disease affecting roughly 1.3 million adults in the United States alone.

TLL-018 is an oral, highly selective dual inhibitor of JAK1 and TYK2—two enzymes implicated in the inflammatory pathways that drive rheumatoid arthritis.

A First-of-Its-Kind Trial

The breakthrough designation stems from results of the Phase III TARA registration study—the world's first Phase III rheumatoid arthritis trial to use an approved JAK inhibitor as an active comparator while achieving a superiority endpoint.

The comparator? Xeljanz (tofacitinib), Pfizer's widely prescribed JAK inhibitor.

The results were striking. TLL-018 demonstrated statistically significant superiority over tofacitinib across the primary endpoint and every secondary efficacy measure, with p-values below 0.0001.

Those measures included the 24-week ACR50 response rate, ACR20 and ACR70 response rates, DAS28 disease activity scores, and CDAI low disease activity.

Addressing an Unmet Need

Perhaps most notably, patients in the tofacitinib group who failed to achieve ACR50 response showed significantly improved efficacy after switching to TLL-018.

That finding suggests TLL-018 may work in patients who have failed both biologic therapies and existing JAK inhibitors—a difficult-to-treat population with no currently approved treatment options.

On safety, the company reported that TLL-018 was generally well tolerated, with no new safety signals observed.

Backed by Patient Capital

Yifeng Capital, which invested in Highlight Pharma during 2020 and 2021, said it will continue supporting the company's mission to bring biotech innovations to market.

The breakthrough designation could accelerate TLL-018's path to approval—and potentially reshape treatment for patients who've run out of options.